3.64
-0.32 (-8.08%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Bearish |
Biotechnology (Global) | Mixed | Bearish | |
Stock | Omeros Corporation | Mixed | Mixed |
Stockmoo Score
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
Ownership
Name | Date | Shares Held |
---|---|---|
Ingalls & Snyder Llc | 30 Jun 2024 | 4,593,148 |
Stifel Financial Corp | 30 Jun 2024 | 1,902,594 |
D. E. Shaw & Co., Inc. | 30 Jun 2024 | 1,576,383 |
Corient Private Wealth Llc | 30 Jun 2024 | 726,451 |
Bank Of Montreal /Can/ | 30 Jun 2024 | 563,096 |
Ubs Group Ag | 30 Jun 2024 | 482,135 |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
07 Aug 2024 | Announcement | Omeros Corporation Reports Second Quarter 2024 Financial Results |
05 Aug 2024 | Announcement | Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |